As this new vasculature is often abnormal and characterized by leaky, poorly perfused vessels that promote tumor cell dissemination and metastasis while limiting immunosurveillance, efforts have been made to inhibit angiogenic signaling pathways [e.g., vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), or fibroblast growth factor (FGF); ref. 6]. The gene discussed is VEGFA; the disease is neoplasm.